 EWING, N.J., July 22, 2021 GLOBE NEWSWIRE -- Antares Pharma, Inc. NASDAQ: ATRS the Company, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration FDA has accepted the Investigational New Drug Application IND for ATRS-1902 for adrenal crisis rescue. The active IND enables Antares to initiate a Phase 1 clinical study for ATRS-1902 for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone. 